Abstract

Mini Review

Non-invasive Serological Markers of Hepatic Fibrosis – Mini Review

Elena Popa*, Raluca Ioana Avram, Andrei Emilian Popa and Adorata Elena Coman

Published: 14 May, 2024 | Volume 8 - Issue 1 | Pages: 032-038

Aim: This study examines the pathological outcomes of chronic liver injuries, with a focus on liver fibrosis. It emphasizes understanding the structural changes within the liver that may lead to cirrhosis and functional impairments, crucial for developing targeted antifibrotic therapies.
Methods: Our approach reviews existing literature detailing the use of traditional diagnostic methods—biochemical and serological tests alongside liver biopsies. Additionally, we evaluate the reliability and efficacy of non-invasive techniques such as serological test panels and imaging examinations. These methods are compared to understand their viability as supplementary or alternative diagnostic tools to liver biopsy.
Significance: Liver fibrosis, if unmanaged, can progress to severe conditions such as cirrhosis and hepatocellular carcinoma, making it vital to understand its progression and treatment options. This study underscores the need for precise and non-invasive diagnostic tools in the clinical management of liver fibrosis, providing insight into the progression of chronic liver diseases and potential therapeutic targets.
Conclusion and future perspectives: The research confirms that while liver biopsy remains the definitive method for staging liver fibrosis, its risks and limitations necessitate the use of enhanced non-invasive diagnostic techniques. These methods have shown promising results in accuracy and are critical for broadening clinical applications and patient safety.
It is recommended that the scientific community continue to develop and validate non-invasive diagnostic tools. Enhancing the accuracy and reliability of these tools can provide a cost-effective, accessible, and safer alternative for large-scale screening and management of liver fibrosis in asymptomatic populations. Additionally, integrating advancements in radiologic and serological markers can further refine these diagnostic methods, improving overall patient outcomes.

Read Full Article HTML DOI: 10.29328/journal.ascr.1001081 Cite this Article Read Full Article PDF

Keywords:

Liver fibrosis; Non-invasive diagnostic methods; Serological markers; Hepatic cirrhosis; Fibrogenesis

References

  1. Curry MP, Afdhal NH. UpToDate [Internet]. Noninvasive Assessment of Hepatic Fibrosis: Overview of Serologic Tests and Imaging Examinations. (Jan 12, 2024). https://www.uptodate.com.
  2. Trifan A, Muzica CM, Nastasa R, Zenovia S, Stratina E, Stafie R, Rotaru A, Singeap AM, Cojocariu C, Sfarti C, Girleanu I, Chiriac S, Cuciureanu T, Huiban L, Stanciu C. High prevalence of liver fibrosis among general population: a Romanian population-based study. Hepatol Commun. 2023 Jan 18;7(2):e0032. doi: 10.1097/HC9.0000000000000032. Erratum in: Hepatol Commun. 2023 Feb 1;7(2):e00c6. Abstract corrected. PMID: 36691959; PMCID: PMC9851682.
  3. Gheorghe G, Bungău S, Ceobanu G, Ilie M, Bacalbaşa N, Bratu OG, Vesa CM, Găman MA, Diaconu CC. The non-invasive assessment of hepatic fibrosis. J Formos Med Assoc. 2021 Feb;120(2):794-803. doi: 10.1016/j.jfma.2020.08.019. Epub 2020 Aug 26. PMID: 32861550.
  4. Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl). 2018 May 9;8:21-29. doi: 10.2147/PTT.S141629. PMID: 29785393; PMCID: PMC5953305.
  5. Joseph J. Serum Marker Panels for Predicting Liver Fibrosis - An Update. Clin Biochem Rev. 2020 May;41(2):67-73. doi: 10.33176/AACB-20-00002. PMID: 32518428; PMCID: PMC7255312.
  6. Wang Z, Zhou Y, Yu P, Liu Y, Mei M, Bian Z, Shao W, Lv J, Li X, Lu W, Xu L. Retrospective Evaluation of Non-Invasive Assessment Based on Routine Laboratory Markers for Assessing Advanced Liver Fibrosis in Chronic Hepatitis B Patients. Int J Gen Med. 2022 May 25;15:5159-5171. doi: 10.2147/IJGM.S364216. PMID: 35642202; PMCID: PMC9148603.
  7. Huang C, Seah JJ, Tan CK, Kam JW, Tan J, Teo EK, Kwek A, Wong YJ, Tan M, Ang TL, Kumar R. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101528. doi: 10.1016/j.clinre.2020.08.006. Epub 2020 Nov 29. PMID: 33268036.
  8. Forsgren MF, Nasr P, Karlsson M, Dahlström N, Norén B, Ignatova S, Sinkus R, Cedersund G, Leinhard OD, Ekstedt M, Kechagias S, Lundberg P. Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. Scand J Gastroenterol. 2020 Jul;55(7):848-859. doi: 10.1080/00365521.2020.1786599. Epub 2020 Jul 20. PMID: 32684060.
  9. Rasmussen DN, Thiele M, Johansen S, Kjærgaard M, Lindvig KP, Israelsen M, Antonsen S, Detlefsen S, Krag A; GALAXY; MicrobLiver consortia. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. J Hepatol. 2021 Nov;75(5):1017-1025. doi: 10.1016/j.jhep.2021.05.037. Epub 2021 Jun 10. PMID: 34118335; PMCID: PMC8522804.
  10. Kaur N, Goyal G, Garg R, Tapasvi C, Chawla S, Kaur R. Potential role of noninvasive biomarkers during liver fibrosis. World J Hepatol. 2021 Dec 27;13(12):1919-1935. doi: 10.4254/wjh.v13.i12.1919. PMID: 35069998; PMCID: PMC8727215.
  11. Bernstein D, Kovalic AJ. Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]. Metabol Open. 2022 Jan 5;13:100158. doi: 10.1016/j.metop.2021.100158. PMID: 35036892; PMCID: PMC8749444.
  12. Canivet CM, Boursier J. Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022? Diagnostics (Basel). 2022 Dec 28;13(1):91. doi: 10.3390/diagnostics13010091. PMID: 36611384; PMCID: PMC9818643.
  13. Lai M, Afdhal NH. Liver Fibrosis Determination. Gastroenterol Clin North Am. 2019 Jun;48(2):281-289. doi: 10.1016/j.gtc.2019.02.002. Epub 2019 Apr 1. PMID: 31046975.
  14. Amernia B, Moosavy SH, Banookh F, Zoghi G. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC Gastroenterol. 2021 Dec 3;21(1):453. doi: 10.1186/s12876-021-02038-3. PMID: 34861841; PMCID: PMC8642865.
  15. Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. Life (Basel). 2021 Feb 14;11(2):143. doi: 10.3390/life11020143. PMID: 33672864; PMCID: PMC7917687.
  16. Blanco-Grau A, Gabriel-Medina P, Rodriguez-Algarra F, Villena Y, Lopez-Martínez R, Augustín S, Pons M, Cruz LM, Rando-Segura A, Enfedaque B, Riveiro M, Casis E, Ferrer-Costa R, Buti M, Rodriguez-Frias F. Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting. Diagnostics (Basel). 2021 Nov 29;11(12):2236. doi: 10.3390/diagnostics11122236. PMID: 34943471; PMCID: PMC8700445.
  17. Drolz A, Wolter S, Wehmeyer MH, Piecha F, Horvatits T, Schulze Zur Wiesch J, Lohse AW, Mann O, Kluwe J. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. Int J Obes (Lond). 2021 Oct;45(10):2197-2204. doi: 10.1038/s41366-021-00881-8. Epub 2021 Jun 24. PMID: 34168277; PMCID: PMC8455320.
  18. Tincopa MA, Loomba R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol. 2023 Jul;8(7):660-670. doi: 10.1016/S2468-1253(23)00066-3. Epub 2023 Apr 13. PMID: 37060912.
  19. Okdemir S, Cakmak E. A novel non-invasive score for the prediction of advanced fibrosis in patients with chronic hepatitis B. Ann Hepatol. 2022 Jan-Feb;27(1):100544. doi: 10.1016/j.aohep.2021.100544. Epub 2021 Sep 24. PMID: 34571267.
  20. Bukhari T, Jafri L, Majid H, Ahmed S, Khan AHH, Abid S, Raza A, Siddiqui I. Diagnostic Accuracy of the Forns Score for Liver Cirrhosis in Patients With Chronic Viral Hepatitis. Cureus. 2021 Apr 13;13(4):e14477. doi: 10.7759/cureus.14477. PMID: 33996335; PMCID: PMC8120009.
  21. Van Dijk AM, Vali Y, Mak AL, Lee J, Tushuizen ME, Zafarmand MH, Anstee QM, Brosnan MJ, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. J Clin Med. 2021 Jun 29;10(13):2910. doi: 10.3390/jcm10132910. PMID: 34209858; PMCID: PMC8269151.
  22. Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol. 2021 Oct;75(4):786-794. doi: 10.1016/j.jhep.2021.05.008. Epub 2021 Jun 4. PMID: 34090928.
  23. Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. Front Med (Lausanne). 2021 Apr 14;8:615978. doi: 10.3389/fmed.2021.615978. PMID: 33937277; PMCID: PMC8079659.
  24. Han MAT. Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. Life (Basel). 2020 Sep 13;10(9):198. doi: 10.3390/life10090198. PMID: 32933184; PMCID: PMC7555355.
  25. Schiavon Lde L, Narciso-Schiavon JL, de Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol. 2014 Mar 21;20(11):2854-66. doi: 10.3748/wjg.v20.i11.2854. PMID: 24659877; PMCID: PMC3961992.
  26. Soresi M, Giannitrapani L, Cervello M, Licata A, Montalto G. Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol. 2014 Dec 28;20(48):18131-50. doi: 10.3748/wjg.v20.i48.18131. PMID: 25561782; PMCID: PMC4277952.
  27. Maroto-García J, Moreno Álvarez A, Sanz de Pedro MP, Buño-Soto A, González A. Serum biomarkers for liver fibrosis assessment. Advances in Laboratory Medicine. Advances in Laboratory Medicine.https://doi.org/10.1515/almed-2023-0081
  28. Aleknavičiūtė-Valienė G, Banys V. Clinical importance of laboratory biomarkers in liver fibrosis. Biochem Med (Zagreb). 2022 Oct 1;32(3):030501. doi: 10.11613/BM.2022.030501. Epub 2022 Oct 1. PMID: 36277426; PMCID: PMC9562801.
  29. Caligiuri A, Gentilini A, Pastore M, Gitto S, Marra F. Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression. Cells. 2021 Oct 15;10(10):2759. doi: 10.3390/cells10102759. PMID: 34685739; PMCID: PMC8534788.
  30. Younesi S, Parsian H. Diagnostic accuracy of glycoproteins in the assessment of liver fibrosis: A comparison between laminin, fibronectin, and hyaluronic acid. Turk J Gastroenterol. 2019 Jun;30(6):524-531. doi: 10.5152/tjg.2019.17339. PMID: 31144658; PMCID: PMC6565348.
  31. Mei L, Ma Y, Zhao L. Correlation between serum liver fibrosis markers and early gastroesophageal varices among patients with compensated liver cirrhosis: a cross-sectional analysis [published correction appears in BMC Gastroenterol. 2023 Mar 30;23(1):99]. BMC Gastroenterol. 2022; 22(1):515. Published 2022 Dec 12. doi:10.1186/s12876-022-02546-w.
  32. Bao J, Ouyang Y, Qiao L, He J, Liu F, Wang Y, Miao L, Fu A, Lou Z, Zang Q, Huang W, Huang J, Li Z. Serum CHI3L1 as a Biomarker for Non-invasive Diagnosis of Liver Fibrosis. Discov Med. 2022 Jan-Feb;33(168):41-49. PMID: 36274212.
  33. Nishimura N, De Battista D, McGivern DR, Engle RE, Tice A, Fares-Gusmao R, Kabat J, Pomerenke A, Nguyen H, Sato S, Bock KW, Moore IN, Kleiner DE, Zamboni F, Alter HJ, Govindarajan S, Farci P. Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):e2019633118. doi: 10.1073/pnas.2019633118. PMID: 33888584; PMCID: PMC8092404.
  34. Naim A, Pan Q, Baig MS. Matrix Metalloproteinases (MMPs) in Liver Diseases. J Clin Exp Hepatol. 2017 Dec;7(4):367-372. doi: 10.1016/j.jceh.2017.09.004. Epub 2017 Oct 3. PMID: 29234202; PMCID: PMC5715451.
  35. Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Ogawa M, Matsuoka S, Karp SJ, Moriyama M. Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives. Int J Mol Sci. 2020 Jul 11;21(14):4906. doi: 10.3390/ijms21144906. PMID: 32664553; PMCID: PMC7402287.
  36. Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells. 2020 Apr 3;9(4):875. doi: 10.3390/cells9040875. PMID: 32260126; PMCID: PMC7226751.
  37. Kimura M, Moteki H, Ogihara M. Role of Hepatocyte Growth Regulators in Liver Regeneration. Cells. 2023 Jan 4;12(2):208. doi: 10.3390/cells12020208. PMID: 36672143; PMCID: PMC9856461.
  38. Bai X, Su G, Zhai S. Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis. Nanomaterials (Basel). 2020 Sep 29;10(10):1945. doi: 10.3390/nano10101945. PMID: 33003520; PMCID: PMC7599596.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?